Business
-
Medical Developments International (MVP) has announced distribution deals for its compact anti-static space chambers in the US and for its Penthrox methoxyflurane inhaler in Russia. All Walmart and Kmart pharmacies in the US will carry… Read more . . .
-
Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said. According to Amneal, the mometasone furoate nasal spray is its “first pharmaceutical product in… Read more . . .
-
Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld… Read more . . .
-
GSK has voluntarily recalled 593,088 Ventolin inhalers manufactured at its Zebulon, North Carolina facility due to an “Elevated number of units with out of specification results for leak rate.” The lots involved in the level… Read more . . .
-
Therapix Biosciences has signed a licensing agreement with Yissum Research Development Company for nasal drug delivery technology that it plans to use for intranasal delivery of cannabinoids, the company said. Yissum Research Development Company is… Read more . . .
-
Sunovion has launched the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD in the United States, the company announced. Sunovion acquired the US rights to the Utibron, Seebri, and Arcapta Neohalers from Novartis in… Read more . . .
-
Verona Pharma has announced a clinical development services agreement with QuintilesIMS for Verona’s RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. The company also said that it is planning… Read more . . .
-
Judge Richard G. Andrews of the US District Court, District of Delaware, has found that Lannett has infringed on the US patents 6,750,237 and 7,220,767 related to Zomig zolmitriptan nasal spray, Impax Laboratories has announced.… Read more . . .
-
According to PARI Pharma, the company has licensed a formulation of liposomal cyclosporine A for the treatment of bronchiolitis obliterans syndrome (BOS) to Breath Therapeutics. Breath Therapeutics, a spin off of PARI, recently announced that… Read more . . .
-
AstraZeneca has announced an agreement with Circassia Pharmaceuticals for development and commercialization of the Tudorza and Duaklir dry powder inhalers in the US. AstraZeneca will receive $50 million in Circassia ordinary shares and $100 million… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden